These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9665503

  • 1. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
    Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul 01; 18(3):252-9. PubMed ID: 9665503
    [Abstract] [Full Text] [Related]

  • 2. Delavirdine: clinical pharmacokinetics and drug interactions.
    Tran JQ, Gerber JG, Kerr BM.
    Clin Pharmacokinet; 2001 Jul 01; 40(3):207-26. PubMed ID: 11327199
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
    Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C, AIDS Clinical Trials Group 365 Study Team.
    Clin Pharmacol Ther; 2003 Mar 01; 73(3):159-69. PubMed ID: 12621381
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
    Tran JQ, Petersen C, Garrett M, Hee B, Kerr BM.
    Clin Pharmacol Ther; 2002 Dec 01; 72(6):615-26. PubMed ID: 12496743
    [Abstract] [Full Text] [Related]

  • 6. Indinavir concentrations and antiviral effect.
    Acosta EP, Henry K, Baken L, Page LM, Fletcher CV.
    Pharmacotherapy; 1999 Jun 01; 19(6):708-12. PubMed ID: 10391416
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
    Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, Freimuth WW.
    Antimicrob Agents Chemother; 1997 Jan 01; 41(1):169-74. PubMed ID: 8980774
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
    Hayashi S, Jayesekera D, Jayewardene A, Shah A, Thevanayagam L, Aweeka F.
    J Clin Pharmacol; 1999 Oct 01; 39(10):1085-93. PubMed ID: 10516944
    [Abstract] [Full Text] [Related]

  • 12. Delavirdine/protease inhibitor interactions.
    Gilden D.
    GMHC Treat Issues; 1996 Sep 01; 10(9):11-2. PubMed ID: 11363839
    [Abstract] [Full Text] [Related]

  • 13. Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.
    Jann MW, Spratlin V, Momary K, Zhang H, Turner D, Penzak SR, Wright A, VanDenBerg C.
    Eur J Clin Pharmacol; 2012 May 01; 68(5):715-21. PubMed ID: 22173281
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M, van der Ende ME.
    Antivir Ther; 2003 Oct 01; 8(5):455-61. PubMed ID: 14640393
    [Abstract] [Full Text] [Related]

  • 16. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.
    Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM.
    Clin Pharmacol Ther; 2002 Jan 01; 71(1):57-67. PubMed ID: 11823758
    [Abstract] [Full Text] [Related]

  • 17. Pharmacology of antiretroviral drugs.
    Hoetelmans RM.
    Antivir Ther; 1999 Jan 01; 4 Suppl 3():29-41. PubMed ID: 16021869
    [Abstract] [Full Text] [Related]

  • 18. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D, Hobbs GR.
    Pharmacotherapy; 2005 Feb 01; 25(2):165-70. PubMed ID: 15767232
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.